Novartis Investigative Site

Teaneck, New Jersey 07666

0 studies enrolling now · 9 studies all time

What they study most

Diabetic Macular Edema, Non-infectious Intermediate Uveitis, Non-infectious Panuveitis, Non-infectious Posterior Uveitis, Non-infectious Uveitis, Primary Progressive Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)

Studies at this site

• Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema — Completed
• Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — Stopped early
• Safety and Efficacy of AIN457 in Noninfectious Uveitis — Completed
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. — Stopped early
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis — Stopped early
• Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis — Stopped early
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed